Maybe they'll let us know the trial is surpassing all positive expectations thus far while side effects remain very few and mild. Prolanta will be a blockbuster. investorshub.advfn.com/uimage/uploads/2017/5/5/imnurdba77d2d7390919aa3c44d77efa326f0.gif